Abstract
Background In Hong Kong, most patients with hepatitis C virus (HCV) have either genotype 6a or 1b infection. Aim To evaluate the efficacy and safety of sofosbuvir with ribavirin in treatment-naïve patients in Hong Kong with HCV genotype 1 or 6. Methods In an open-label study, patients were randomised to sofosbuvir 400 mg once daily plus ribavirin 1000-1200 divided twice daily for 12 (n = 10), 16 (n = 11) or 24 (n = 10) weeks. The primary endpoint was the percentage of patients with HCV RNA
Cite
CITATION STYLE
Lai, C. L., Wong, V. W. S., Yuen, M. F., Yang, J. C., Knox, S. J., Mo, H., … Chan, H. L. Y. (2016). Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Alimentary Pharmacology and Therapeutics, 43(1), 96–101. https://doi.org/10.1111/apt.13429
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
